Does the media prefer ADMA or LGND?

In the previous week, ADMA Biologics had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 15 mentions for ADMA Biologics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat ADMA Biologics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIP or LGND?

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 4 mentions for ANI Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat ANI Pharmaceuticals' score of 1.06 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LGND or NBIX?

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Neurocrine Biosciences' score of 0.64 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EXEL or LGND?

In the previous week, Exelixis had 33 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 42 mentions for Exelixis and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Exelixis' score of 0.75 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 16 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IONS or LGND?

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for Ionis Pharmaceuticals and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Ionis Pharmaceuticals' score of 1.05 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ligand Pharmaceuticals (LGND) Competitors

$232.74 -1.92 (-0.82%)

As of 01:10 PM Eastern

Compare

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

Should you buy Ligand Pharmaceuticals stock or one of its competitors? MarketBeat compares Ligand Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, ADMA Biologics had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 15 mentions for ADMA Biologics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat ADMA Biologics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.70	$146.93M	$0.68	11.98
Ligand Pharmaceuticals	$268.09M	17.40	$124.45M	$7.37	31.58

Ligand Pharmaceuticals has a net margin of 55.95% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

ADMA Biologics presently has a consensus target price of $19.00, indicating a potential upside of 133.27%. Ligand Pharmaceuticals has a consensus target price of $257.71, indicating a potential upside of 10.73%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

ADMA Biologics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

ANI Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.06	$78.34M	$3.95	20.26
Ligand Pharmaceuticals	$268.09M	17.40	$124.45M	$7.37	31.58

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 4 mentions for ANI Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat ANI Pharmaceuticals' score of 1.06 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals currently has a consensus price target of $107.33, suggesting a potential upside of 34.10%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential upside of 10.73%. Given ANI Pharmaceuticals' higher possible upside, equities analysts plainly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Ligand Pharmaceuticals (NASDAQ:LGND) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Neurocrine Biosciences has higher revenue and earnings than Ligand Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	17.40	$124.45M	$7.37	31.58
Neurocrine Biosciences	$2.86B	5.59	$478.60M	$6.49	24.49

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Ligand Pharmaceuticals currently has a consensus target price of $257.71, suggesting a potential upside of 10.73%. Neurocrine Biosciences has a consensus target price of $186.05, suggesting a potential upside of 17.06%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Neurocrine Biosciences' score of 0.64 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Exelixis presently has a consensus price target of $47.35, suggesting a potential downside of 7.62%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential upside of 10.73%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Exelixis has higher revenue and earnings than Ligand Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.55	$782.57M	$3.01	17.03
Ligand Pharmaceuticals	$268.09M	17.40	$124.45M	$7.37	31.58

Exelixis has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Exelixis had 33 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 42 mentions for Exelixis and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Exelixis' score of 0.75 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	16 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for Ionis Pharmaceuticals and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Ionis Pharmaceuticals' score of 1.05 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Ionis Pharmaceuticals' net margin of -30.91%. Ligand Pharmaceuticals' return on equity of 16.19% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.6% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.64	-$381.39M	-$2.07	N/A
Ligand Pharmaceuticals	$268.09M	17.40	$124.45M	$7.37	31.58

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Ionis Pharmaceuticals currently has a consensus target price of $100.90, suggesting a potential upside of 29.52%. Ligand Pharmaceuticals has a consensus target price of $257.71, suggesting a potential upside of 10.73%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Ligand Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.66B	$3.40B	$6.42B	$12.60B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	31.58	18.93	21.28	26.32
Price / Sales	17.40	333.54	558.91	114.49
Price / Cash	30.04	125.26	43.49	56.90
Price / Book	4.68	7.29	10.60	7.34
Net Income	$124.45M	$24.20M	$3.56B	$337.06M
7 Day Performance	1.49%	4.37%	3.21%	3.67%
1 Month Performance	3.50%	9.71%	6.51%	7.41%
1 Year Performance	130.64%	63.73%	36.74%	37.93%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	3.4815 of 5 stars	$232.74 -0.8%	$257.71 +10.7%	+134.2%	$4.66B	$268.09M	31.58	80	Positive News
ADMA ADMA Biologics	4.7855 of 5 stars	$8.24 -2.6%	$19.00 +130.6%	-59.4%	$1.91B	$510.17M	12.12	530	Analyst Downgrade
ANIP ANI Pharmaceuticals	3.627 of 5 stars	$82.72 -0.1%	$107.33 +29.8%	+40.3%	$1.88B	$923.71M	20.94	600	Positive News
NBIX Neurocrine Biosciences	4.4309 of 5 stars	$156.70 +0.8%	$185.90 +18.6%	+27.1%	$15.76B	$3.10B	24.14	2,000	Analyst Forecast Insider Trade
EXEL Exelixis	2.7066 of 5 stars	$50.15 +1.0%	$47.35 -5.6%	+21.3%	$12.61B	$2.32B	16.66	1,077	Trending News Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Ligand Pharmaceuticals compare to Exelixis?

Summary

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Does the media prefer ADMA or LGND?

Which has preferable valuation and earnings, ADMA or LGND?

Is ADMA or LGND more profitable?

Do analysts prefer ADMA or LGND?

Which has more volatility and risk, ADMA or LGND?

Do institutionals & insiders believe in ADMA or LGND?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Which has more volatility & risk, ANIP or LGND?

Is ANIP or LGND more profitable?

Do insiders and institutionals have more ownership in ANIP or LGND?

Which has better earnings and valuation, ANIP or LGND?

Does the media prefer ANIP or LGND?

Do analysts prefer ANIP or LGND?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Is LGND or NBIX more profitable?

Which has stronger valuation and earnings, LGND or NBIX?

Do insiders & institutionals have more ownership in LGND or NBIX?

Which has more risk and volatility, LGND or NBIX?

Do analysts prefer LGND or NBIX?

Does the media refer more to LGND or NBIX?

Summary

How does Ligand Pharmaceuticals compare to Exelixis?

Do institutionals and insiders have more ownership in EXEL or LGND?

Is EXEL or LGND more profitable?

Do analysts recommend EXEL or LGND?

Which has higher earnings and valuation, EXEL or LGND?

Which has more risk and volatility, EXEL or LGND?

Does the media prefer EXEL or LGND?

Summary

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Does the media prefer IONS or LGND?

Is IONS or LGND more profitable?

Do insiders & institutionals have more ownership in IONS or LGND?

Which has stronger valuation & earnings, IONS or LGND?

Which has more risk & volatility, IONS or LGND?

Do analysts recommend IONS or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools